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PMEETING HIGHLIGHTS
Highlights of the 2009 Scientific Sessions
of the European Society of Cardiology
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she annual congress of the European Society of Cardiology
ESC) was held in Barcelona, Spain, August 29 to Septem-
er 2, 2009. The total attendance was 31,323 participants
rom 136 different countries. Excellent congress facilities
osted 237 pre-arranged sessions in 30 meeting rooms
unning in parallel, including several joint sessions in
ollaboration with other societies (e.g., the American Col-
ege of Cardiology, the American Heart Association, and
he World Heart Federation). A total of 9,848 abstracts
rom 96 different countries was submitted, and 4,085 (42%)
bstracts were selected for presentation.
revention
revention was the theme of this year’s meeting, and
nteresting novelties were presented. From the Copenhagen
rom *Leiden University Medical Center, Leiden, the Netherlands; †Department of
ardiovascular Medicine, University of Oxford, Oxford, United Kingdom; ‡Royal
rompton Hospital, London, United Kingdom; §University Hospitals Leuven (K.U.
euven), Leuven, Belgium; Athens University Hospital Attikon, Athens, Greece;
University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom;
University of Brescia, Brescia, Italy; **Hammersmith Hospital, NHLI, Imperial
ollege London, London, United Kingdom; ††Kalmar University, Kalmar, Sweden;
‡Medical University of Vienna, Vienna, Austria; §§Heraklion University Hospital,
rete, Greece;  Lisbon University Medical School, Lisbon, Portugal; and the
¶University of Ferrara and Salvatore Maugeri Foundation, IRCCS, Ferrara, Italy.
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eart rate was linearly related to fibrinogen and high-
ensitivity C-reactive protein plasma levels. After adjust-
ent for inflammatory markers, heart rate remained an
ndependent risk factor for both cardiovascular (CV) and
ll-cause mortality: the relative risk (RR) for CV mortality
as 1.2 (p  0.001) for each 10 beats/min increase of heart
ate.
Among300,000 French adults, Plichart et al. (2) found
ncrements of 7 beats/min and 5 beats/min in resting heart
ates in women and men, respectively, in the decade 1990 to
000; no further change was noted in the last decade. This
uzzling finding could not be explained by conventional risk
actors, medication, or physical activity, and prognostic
mplications remain to be demonstrated.
The outcome of the French law on a smoke-free envi-
onment in public places inspired Bura et al. (3) to study the
ffect of this law on employees in bars and restaurants.
omparison of 23 nonactive smokers exposed to passive
moking in the workplace (but not exposed at home) and 23
ontrols (exposed neither at work nor at home) showed a
ignificant reduction in flow-mediated dilation (5.8% vs.
.1%) before application of the law. This was almost
ormalized 4 months after the law was imposed: 8.3%
ersus 9.5%, illustrating the impact of smoking restriction
n vascular function.
Pereg et al. (4) evaluated the role of stress in patients with
cute myocardial infarction (MI) and compared hair sam-
les from 45 patients admitted for acute MI with samples
rom 45 patients admitted for noncardiac causes. The
uthors reported a significant increase in hair cortisol levels:
20 ng/g (range 102 to 937 ng/g) versus 231 ng/g (range 82
o 1,123 ng/g; p  0.001), respectively. This observation
uggests that infarct patients may have experienced chronic
tress during the 3 months preceding the acute event.
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2009 Scientific Sessions of the ESC December 15/22, 2009:2447–58The winners of the featured research award session were
rbs et al. (5) from Leipzig, who studied 80 obese children
body mass index 28 kg/m2) and 60 lean children (body
ass index 18 kg/m2). Peak serum insulin levels after an oral
lucose tolerance test were considerably higher among the
bese children: 1,079  80 pmol/l versus 598  23 pmol/l
p  0.001). Flow-mediated dilation was impaired in the
bese children, and the intima media thickness in the
arotid artery was increased. The endogenous regenerative
apacity, expressed as the number of circulating endothelial
rogenitor cells, was impaired. Thus, childhood obesity
ppears to be associated with early stages of atherosclerosis.
Children are recommended to engage in 1 h per day of
hysical activity. Walther et al. (6) showed that 12-year-old
hildren with a higher level of physical activity (15 h
eekly) had a significant beneficial impact on a range of
arkers of vascular function when compared with less active
ge-matched controls participating only in school exercise
essons (2 to 3 h weekly).
The role of regular physical activity on surrogate
arkers of vascular aging (telomere length in leukocytes)
as investigated by Werner et al. (7). They compared
oung athletes and nonsmoking healthy volunteers (mean
ge 21 years) and found no difference in telomere length
t this age level. Telomeres do shorten with increasing
ge. However, when older athletes were compared with
ge-matched less active controls (mean age 51 years), the
thletes had a significant inhibition of the telomere
rosion, indicating a potent “anti-aging” effect of regular
hysical activity.
Earlier surveys, namely, EuroAspire III, have shown a
arge gap between recommendations and clinical practice in
ardiovascular disease (CVD) prevention. In England, Jones
t al. (8) have started novel family-centered community-
ased programs in which multidisciplinary teams of health
orkers provide preventive care for CVD patients, for
ersons at high CVD risk, and for their families. A first
valuation suggested that this model is effective and should
e extended beyond the already 15 existing centers in the
ountry.
Garzia et al. (9) studied the effect of acute, moderate red
ine consumption (5 ml/kg) in 40 young volunteers as
ompared with consumption of nonalcoholic beverages:
cute intake of red wine appeared to be associated with an
ncrease in various electrocardiography (ECG) time inter-
als, which may indicate a potential arrhythmogenic risk of
ed wine consumption.
Barone Adesi et al. (10) evaluated the possibility of
ncreased risk for acute coronary syndromes (ACS) in the
iedmont area in Italy in relation to watching soccer
atches. Studying the relative risk of hospital admissions
or ACS during the Soccer World Championships in 2002
nd 2006 and the European Championship in 2004 revealed
o increase in admissions, in contrast to earlier findings. mypertension
n the Malmö Prevention Project, a cohort of 33,346
ubjects (ages 45.7  7.4 years) was followed up for 22.7 
.0 years (11). Orthostatic hypotension, defined as systolic
lood pressure (BP) fall 20 mm Hg and/or diastolic BP
all 10 mm Hg within 3 min of standing, was present in
% of the participants. After adjustment for traditional risk
actors, orthostatic hypotension moderately increased mor-
ality (hazard ratio [HR]: 1.19, p  0.001) and coronary
vents (HR: 1.18, p  0.01), but not stroke. The authors
lso assessed the prognostic significance when orthostatic
ypotension was defined as systolic BP fall 30 mm Hg
nd diastolic BP fall 15 mm Hg, which distinctly in-
reased mortality and coronary event risks, with HRs of 1.40
o 1.65. In the PAMELA (Pressioni Arteriose Monitorate
Loro Associazioni) study on ambulatory BP monitoring, a
ohort of 2,011 subjects (ages 25 to 74 years) representative
f the general population of Monza was followed up for an
verage of 12.3 years (12). Morning BP surge was defined as
he average systolic BP 2 h after awakening minus the
owest night-time systolic BP. In univariable analysis, the
orning BP surge predicted all-cause mortality and CV
vents, but the relationships disappeared after adjustment
or potential confounders, such as age and other 24-h BP
ariables. The authors concluded that morning BP surge
eflects overall BP variability but does not independently
redict mortality. However, one has to consider that there is
o generally accepted definition of morning BP surge, and
efinitions usually lack the concept of “morning surge.”
Moderate aerobic exercise is a generally accepted non-
harmacological measure in the management of hyperten-
ion. In a study from Norway, 89 patients (49 men) with
rades I to II essential hypertension (age 52  8 years) were
andomly divided into 3 groups: aerobic interval training at
5% of peak heart rate; isocaloric moderate continuous
raining at 70% of peak heart rate; and a control group (13).
fter 12 weeks, BP decreased by 13/7 mm Hg in the
nterval training group, by 4/4 mm Hg in the continuous
raining group, and remained unchanged in the control
roup. The authors concluded that both training modalities
ignificantly reduce BP, but that interval training appears to
e more effective than continuous training.
The double-blind placebo-controlled HYVET (Hyper-
ension in the Very Elderly Trial) has shown benefit from
ntihypertensive treatment in octogenarians. The investiga-
ors presented the results from the study extension, in which
,712 patients were actively treated (14). Comparing pa-
ients previously treated with active medication to patients
reviously on placebo, significant benefit was found for total
nd CV mortality, and no differences were seen for stroke or
eart failure (HF). Therefore, octogenarians gained imme-
iate benefit from treatment in the prevention of stroke and
F, but sustained differences with regard to reductions in
otal and CV mortality reinforce the need for early treat-
ent.
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December 15/22, 2009:2447–58 2009 Scientific Sessions of the ESCIn the joint session of the ESC and the European Society
f Hypertension (ESH), the question was asked: what is
ew, what can be reinforced, and what may have to be
hanged in 2009 with regard to the 2007 ESC/ESH
ypertension guidelines? The importance of global CV risk
n the basis of risk factors, subclinical organ damage, and
V renal disease was re-emphasized. With regard to first-
hoice drugs, the position that all drugs have pros and cons
nd that no drug should be generally prescribed or pro-
cribed was maintained. The role of combination treatment
as reinforced by the evidence that initiation with combi-
ation treatment is associated with earlier BP control and
etter tolerability and compliance, and that adding a drug
rom another class is more effective than doubling the dose
f the same drug. On the basis of the pronounced antihy-
ertensive effect, evidence of CV protection, and optimal
olerability in recent trials, some combinations of drugs can
e promoted to most-preferred combinations, namely, di-
retics or calcium antagonists with angiotensin-converting
nzyme inhibitors or angiotensin-receptor blockers. Blood
ressure thresholds and goals for drug treatment may need
ritical reappraisal, because in several instances they are not
ased on results from prospective outcome trials. Data from
ther sources may justify current recommendations, but
urther hard evidence is needed. In addition, the BP level
elow which vital organ perfusion is impaired is likely to
iffer according to patient characteristics; for example,
ost-hoc analyses of trials suggest that there is some reason
or concern when high-risk patients’ on-treatment BP is
120/75 mm Hg. Finally, new evidence for treatment in
pecific conditions includes the HYVET trial, which
howed that even octogenarians benefit from antihyperten-
ive therapy.
F
he prognosis of the patients with HF remains poor.
ccurate prognostic stratification is, therefore, still impor-
ant, and biomarkers represent a major objective of research.
he independent prognostic values of increased serum urea
evels during hospitalization (15), as well as of cystatin C
16), red cell distribution width (17), troponin I (measured
y a highly sensitive assay) (18), and arginine-vasopressin
nd adrenomedullin plasma levels (19) were shown.
In HF patients with preserved left ventricular ejection
raction (LVEF), independent prognostic factors, as as-
essed in the I-PRESERVE (Irbesartan in HF With
reserved Ejection Fraction) study, were N-terminal pro–
-type natriuretic peptide (NT-proBNP), age, diabetes
ellitus, and previous HF hospitalization (20). In 60% of
eaths, the cause was CV, mostly due to sudden death or
orsening HF (21).
Diabetes is a known risk factor for HF, and antidiabetic
reatment may affect outcome. In the RECORD (Rosigli-
azone Evaluated for Cardiovascular Outcomes in Oral
gent Combination Therapy for Type 2 Diabetes) study, HV outcomes were prospectively assessed after addition of
osiglitazone to either metformin or sulfonylurea, compared
ith the combination of the 2 alone in 4,447 patients with
ype 2 diabetes (22). The incidence of CV hospitalization or
eath (primary end point), as well as CV death, stroke, and
I, were similar between the 2 study groups. However, the
ncidence of deaths or hospitalizations caused by HF was
reater among the patients treated with rosiglitazone (61
ubjects vs. 29 subjects in the control group; HR: 2.1, 95%
I: 1.35 to 3.27).
Tachycardia may have a role as a determinant of HF.
owever, in the BEAUTIFUL (Morbidity-Mortality Eval-
ation of the If Inhibitor Ivabradine in Patients With
oronary Disease and Left Ventricular Dysfunction) trial,
ure heart rate reduction with ivabradine had no effect on
he primary composite end point of CV death or readmis-
ion due to HF or MI. In a subgroup analysis concentrating
n the patients with limiting angina at baseline, ivabradine
id not affect the rate of HF hospitalizations but did reduce
dmissions for MI, particularly among patients with heart
ate at baseline 70 beats/min (23).
Rosuvastatin did not change major outcomes in the
ISSI-HF (Gruppo Italiano per lo Studio della Sopravvi-
enza nell’Infarto Miocardico–Heart Failure) trial (24).
here are some data that statins may reduce the incidence of
trial fibrillation (AF). Among the 3,690 patients without
F at baseline in the GISSI-HF trail, AF developed in
5.0% during a median follow-up of 3.7 years (13.9% with
osuvastatin vs. 16.0% with placebo). Although the differ-
nce was not significant at unadjusted analysis (p  0.097),
t was significant after adjustment for other clinical and
aboratory variables (p  0.039). These data suggest that
osuvastatin may have beneficial effects on AF occurrence in
atients with HF.
The use of cardiac resynchronization therapy (CRT) for
F is increasing, and has been evaluated in a survey
rganized by ESC associations on heart failure and heart
hythm (25). This survey included 2,438 patients from 141
enters in 12 European countries and Israel who underwent
uccessful CRT implantation. Approximately 80% of pa-
ients who underwent CRT implantation were in New York
eart Association (NYHA) functional class III or IV, but
% were in NYHA class I and 20% were in NYHA class II.
pproximately 80% of patients had QRS duration 130
s, but 9% had QRS duration 120 ms, and 10% had
urations between 120 ms and 130 ms. The vast majority
ad sinus rhythm, but 23% had AF, and 26% concerned
pgrades from permanent right ventricular pacing or im-
lantable cardioverter-defibrillator (ICD). Periprocedural
omplications occurred during 11% of the procedures.
The hypothesis that an adenosine-blocking agent, rolo-
ylline, could induce diuresis, prevent deterioration of renal
unction, and improve 60-day outcomes of patients with
cute HF was tested in the PROTECT (Placebo-
ontrolled Randomized Study of Rolofylline for Patients
ospitalized With Acute HF and Volume Overload to
A
t
v
w
c
s
p
a
(
n
a
i
h
g
c
(
w
d
s
t
g
fl
e
i
r
a
s
a
a
b
t
n
d
B
d
A
T
c
n
h
p
w
g
n
f
d
E
a
h
n
o
4
w
s
1
s
(
w
0
n
i
e
c
c
b
o
w
m
a
d
T
a
s
d
A
A
A
i
M
w
i
f
s
d
i
w
O
t
s
o
i
v
s
p
s
t
a
s
d
v
b
2450 Bax et al. JACC Vol. 54, No. 25, 2009
2009 Scientific Sessions of the ESC December 15/22, 2009:2447–58ssess Treatment Effect on Congestion and Renal Func-
ion) study (presented at ESC Hotlines). The study in-
olved 2,033 patients hospitalized within 24 h of acute HF,
ith high BNP or NT-proBNP and an estimated creatinine
learance of 20 to 80 ml/min. The results failed to show the
uperiority of rolofylline on the composite primary end
oint, renal function and outcomes. Rolofylline was associ-
ted with more improvement in dyspnea at 24 to 48 h
51.2% vs. 44.5% with placebo). Regarding safety, there was
o difference in serious adverse events, but rolofylline was
ssociated with seizures (0.8% vs. 0%) and a tendency to an
ncrease in the number of strokes, either ischemic or
emorrhagic (1.2% vs. 0.5%), versus placebo.
For patients presenting with acute HF, predictors of a
reater response of dyspnea to the new vasodilator relaxin,
ompared with placebo, were higher systolic BP at baseline
26), and a shorter time to treatment (27). Inotropic agents
ith novel mechanisms of action are currently studied. The
irect cardiac myosin activator CK-1827452 has been
hown to cause a dose-dependent increase in systolic ejec-
ion time, stroke volume, and LVEF. As excessive prolon-
ation of systolic ejection time can limit diastolic coronary
ow and ventricular filling, the effects of CK-1827452 on
xercise tolerance have been studied in 94 patients with
schemic cardiomyopathy and angina using a double-blind,
andomized, placebo-controlled study design. The myosin
ctivator did not adversely affect exercise capacity and
howed a good safety profile in these patients (28).
Beta-blockers have improved outcomes even when ther-
py is maintained in patients with acute HF, in retrospective
nalyses. The effects of maintenance of ongoing beta-
locker therapy, versus its withdrawal, was prospectively
ested in 169 patients hospitalized for acute HF. Mainte-
ance of ongoing beta-blocker therapy had no effect on
yspnea relief nor on other end points, including plasma
NP, length of hospital stay, rehospitalization rate, and
eath rate after 3 months (29).
cute Cardiac Care
he majority of successfully resuscitated out-of-hospital
ardiac arrest patients will die during hospital stay. Giovan-
etti et al. (30) have shown, for 983 patients with out-of
ospital arrest, that the mortality among patients with a
rimary cardiac cause was lower (58%) than among patients
ith an extracardiac cause (80%; p  0.001). Current
uidelines recommend coronary angiography and percuta-
eous coronary intervention (PCI) for patients resuscitated
rom cardiac arrest due to ACS. However, it usually is
ifficult to identify the cause of arrest, and the value of the
CG is controversial. Dumas et al. (31) performed coronary
ngiography in all arrest survivors (n  372) who did not
ave an obvious cause of arrest. After the return of sponta-
eous circulation, ST-segment elevation was noted in 30%
f patients, ST-segment depression or negative T waves in
9%, and nonspecific changes or normal ECG in 21%. PCI ras more frequently performed in patients with ST-
egment elevation (80%) than in the other groups (28% and
8%, respectively; p  0.0001). Overall, 41% of patients
urvived during their hospital stay. The survival was higher
51%) among patients with ST-segment elevation compared
ith the other 2 groups (41% and 27%, respectively; p 
.005).
Mild induced hypothermia lowers mortality and reduces
eurologic damage after cardiac arrest. Current techniques
nvolving total body cooling have many limitations and side
ffects. Salinas Sanguino et al. (32) have shown that ECG
hanges during mild induced hypothermia are similar to
hanges that occur with deep accidental hypothermia. Sinus
radycardia was the most common arrhythmia. Durations
f PR, QTc, and QRS are prolonged, and changes revert
ith rewarming.
A new catheter that selectively cools the brain while
aintaining normal systemic temperature has been evalu-
ted in an animal model and may improve neuroprotection
uring cardiac arrest without adverse events (33). Moreover,
useth et al. (34) have shown in an experimental model that
percutaneous LV assist device can achieve hemodynamic
upport comparable to that of open chest cardiac massage
uring cardiac arrest.
CS
n updated analysis of the TRITON–TIMI 38 (Trial to
ssess Improvement in Therapeutic Outcomes by Optimiz-
ng Platelet Inhibition With Prasugrel–Thrombolysis In
yocardial Infarction 38) study examined whether there
as an interaction between the use of proton-pump inhib-
tors and thienopyridines (35). In contrast to the reports
rom observational studies, the data from this trial did not
how evidence of a difference in outcomes for either clopi-
ogrel or for prasugrel, with or without proton-pump
nhibitors (but lower event rates with prasugrel compared
ith clopidogrel).
Similarly, in the CURRENT–OASIS 7 (Clopidogrel
ptimal Dose to Reduce Recurrent Events–Organization
o Assess Strategies for Ischemic Syndromes 7) trial (pre-
ented at the ESC Hotlines), no difference in outcomes was
bserved for patients taking or not taking proton-pump
nhibitors. The findings suggest that unmeasured baseline
ariables may have contributed to the excess risk seen in
ome observational reports of concomitant administration of
roton-pump inhibitors and thienopyridines.
The ESC non–ST-segment elevation ACS guidelines
uggested that a 600 mg bolus of clopidogrel could be given
o patients with planned PCI, in addition to aspirin and an
nticoagulant, but the guideline highlighted that a definitive
tudy was needed. The CURRENT–OASIS 7 trial ran-
omly assigned 25,087 patients with non–ST-segment ele-
ation ACS to a strategy of higher (600 mg bolus followed
y 150 mg for 1 week, followed by 75 mg daily) or standard
egimen of clopidogrel (300 mg bolus followed by 75 mg
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December 15/22, 2009:2447–58 2009 Scientific Sessions of the ESCaily). In this double-blind comparison, the primary out-
ome was CV death, MI, or stroke at 30 days, and the intent
as to study these dosing regimens of clopidogrel in the
ontext of PCI. The study also included an open factorial
esign of the first large-scale randomized comparison of
spirin dose (75 to 100 mg vs. 300 to 325 mg over 30 days).
n the overall population, the primary end point was similar
or the 2 clopidogrel strategies, but in the pre-specified
nalysis of the 17,232 patients undergoing PCI, there were
ignificantly fewer combined end points of CV death, MI,
r stroke with the higher-dose regimen (4.5% standard
ose, 3.9% double dose, HR: 0.85, 95% CI: 0.74 to 0.99;
 0.036). The higher-dose regimen also demonstrated a
educed rate of stent thrombosis (HR: 0.58, 95% CI: 0.42 to
.79; p 0.001). In contrast, for the 7,855 patients without
CI, there was no benefit in this short-term study (30-day
utcomes). In the entire study, the rates of TIMI major
leeding were not different for the higher versus lower
lopidogrel regimens (0.5% vs. 0.5%), but there were more
ransfusions of 2 or more units with the higher clopidogrel
trategy. In the randomized comparison of aspirin dose.
here was neither overall benefit nor greater bleeding risk for
he higher-dose regimen. However, the factorial analysis
uggests that most benefit may be seen for the high-dose
spirin, high-dose clopidogrel regimen.
The PLATO (Platelet Inhibition and Patient Outcomes)
rial tested ticagrelor, an orally active and reversible non-
hienopyridine P2Y12 antagonist, against clopidogrel (300
g bolus and 75 mg daily) in 18,624 patients with non–
T-segment elevation ACS or ST-segment elevation ACS
ith planned primary PCI (36). An additional 300 mg bolus
f clopidogrel was allowed for PCI and was given to 19%
f all patients. The double-blind regimen was administered
or a median of 9 months, and the primary outcome of CV
eath, MI, or stroke occurred in 9.8% of patients receiving
icagrelor compared with 11.7% of patients receiving clopi-
ogrel (HR: 0.84, 95% CI: 0.77 to 0.92; p  0.001). The
uthors pre-defined a system of hierarchical testing of
econdary end points. This revealed significant differences in
he rates of MI alone (5.8% in the ticagrelor group vs. 6.9%
n the clopidogrel group, p  0.005), and deaths from CV
auses (4.0% with ticagrelor vs. 5.1% with clopidogrel, p 
.001) but not stroke alone (1.5% vs. 1.3%, p  0.22).
eath from any cause was also reduced with ticagrelor
4.5%, vs. 5.9% with clopidogrel, p  0.001). There was no
ignificant difference in the rate of major bleeding between
he ticagrelor and clopidogrel groups (11.6% and 11.2%,
espectively), but ticagrelor was associated with a higher rate
f major bleeding unrelated to coronary artery bypass graft
urgery (CABG) (4.5% vs. 3.8% with clopidogrel, p 
.03), and more cases of fatal intracranial bleeding (11 vs. 1,
espectively, p  0.02) but fewer cases of fatal nonintracra-
ial bleeding. Thus, compared with the currently published
uidelines for the standard of care for patients with ACS,
reatment with ticagrelor compared with clopidogrel signif-
cantly reduced the composite of death from CV causes, MI, br stroke without an increase in the rate of overall major
leeding but with an increase in the rate of non–procedure-
elated bleeding.
These recent PLATO study results need to be evaluated
n the light of the earlier findings from the TRITON–TIMI
8 study in which superior efficacy was demonstrated for
rasugrel over clopidogrel, but at the expense of higher rates
f major bleeding, especially in certain high-risk groups
35). In contrast to the TRITON–TIMI 38 study, in which
he study drugs were administered after diagnostic angiog-
aphy, the PLATO study randomized patients with ST-
egment and non–ST-segment elevation ACS after first
resentation. Whether prasugrel offers advantages over ti-
agrelor among unselected patients with the full spectrum of
CS remains to be determined.
nterventional Cardiology
n a session entitled “Three years after Barcelona 2006,”
ames presented for the first time the 6-year follow-up of
0,937 patients enrolled in the SCAAR (Swedish Coronary
ngiography Angioplasty Registry) study, equally divided
etween patients treated with bare-metal stents or drug-
luting stents (DES). The Kaplan-Meier curves for adjusted
ortality and MI reported for single stents, for the overall
opulation, and for on- or off-label indications were super-
mposable.
The ESTROFA-2 (Estudio Español Sobre Trombosis
e Stents Farmacoactivos-2) registry closely followed 4,768
atients treated with second-generation DES (the
otarolimus-eluting stent Endeavor and the everolimus-
luting stent Xience/Promus) enrolled in 34 Spanish centers
etween 2006 and April 2008 (37). Definite thrombosis rate
t 2 years was low (1.0% for zotarolimus-eluting and 0.9%
or everolimus-eluting stents), with a particularly low inci-
ence in the interval between 12 and 24 months (0.2% and
.1%, respectively). The largest randomized comparison of
ES with biodegradable and biostable polymers was re-
orted by the ISAR (Intracoronary Stenting and Angio-
raphic Results) study investigators (38). The stent studied
as developed in Munich, Germany, and elutes sirolimus
or 4 to 6 weeks after implant through a polymer expected
o be fully absorbed by the surrounding tissue after 6 to 9
onths. The 1,299 patients treated with this stent were
ompared with 1,304 patients receiving conventional com-
ercially available sirolimus- and everolimus-eluting stents
Cypher [Cypher Corp., Bridgewater, New Jersey] and
ience [Abbott Laboratories, Abbott Park, Illinois]). At the
- to 8-month angiographic follow-up, late lumen loss was
.24 and 0.26 mm for the stents with biodegradable and
iostable polymers, respectively. The similar restenosis rate
xplained the nearly identical rate of repeat revascularization
t 12 months (13.7% and 13.9%). Death and MI were also
imilar in the 2 groups, with a definite stent thrombosis at
year of 1.5% for the biostable stent and 1.0% for the
iodegradable polymer stent platforms (p  0.29). Nasu et
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irolimus-eluting (Cypher) and 60 paclitaxel-eluting
Taxus, Boston Scientific, Natick, Massachusetts) stents.
ix months after implantation, there was absent or incom-
lete tissue coverage in 18% of Taxus stents versus 33% of
ypher stents (p  0.03). More than 20% of struts
emained uncovered in 5% and 37%, respectively, of the
aclitaxel- and sirolimus-eluting stents (p  0.03). In a
eparate study, 24 patients received a Cypher stent and a
axus stent in the same artery. Six months after implanta-
ion, 4.6% and 11.1% of the apposed struts were uncovered
n the respective groups, and they also differed in the average
eointimal thickness, which was greater in Taxus stents
150  163 m vs. 94  103 m for Cypher stents, p 
.01) (40).
There was great expectation for the update of the SYN-
AX (Synergy Between PCI With Taxus and Cardiac
urgery) trial. The main criticism, particularly from cardiac
urgeons, was that the equivalence in major hard end points
death, MI, stroke) at 1 year was not going to hold with
ime and that the difference in new revascularizations, which
lready drew at 1 year the major adverse cardiac and
erebrovascular events rate in favor of surgery (12.1% vs.
7.8%, p  0.002), was due to progressive increase over
ime. The 2-year results showed no difference in the
ncidence of additional deaths and strokes (presented at
SC Clinical Trial Updates). Myocardial infarction after
he first year, on the contrary, occurred more frequently
mong the 903 patients treated with Taxus stents (1.2% vs.
.1% in the surgery group, p  0.008), leading to an overall
reater frequency 2 years after treatment in the Taxus group
5.9% vs. 3.3% in the surgical group, p  0.01). Still, there
as no overall difference in the combined end point of
eath, MI, or stroke at 2 years (10.8% in the Taxus group
nd 9.4% in the CABG group, p  0.44). Unexpectedly,
evascularization between 1 and 2 years was not significantly
ifferent in the 2 groups (3.4% for CABG, 4.7% for Taxus,
 0.06), with most of the absolute difference at 2 years
8.6% vs. 17.4%, p  0.001) occurring between 6 and 12
onths and relatively flat, nearly parallel curves between 18
nd 24 months. The overall event rate at 2 years remained
ignificantly lower with CABG (16.3% vs. 23.4% with
axus, p  0.001), but groups with a low and intermediate
YNTAX score (33) and the 707 patients with left main
isease showed no significant difference. An update in
esults (from 12 to 18 months) was also shown by the
AME (Fractional Flow Reserve Versus Angiography for
ultivessel Evaluation) study investigators (presented at
SC Clinical Trial Updates). The study randomly allocated
,005 patients with multivessel disease to angioplasty of all
ngiographically significant stenoses or to selective angio-
lasty only of lesions with a fractional flow reserve 0.80.
he significant difference in major adverse cardiac events
bserved at 1 year in the group with a flow reserve guided
pproach (5.1%) had a further increase in the subsequent emonths (5.3%), dispelling criticisms that leaving inter-
ediate lesions untreated creates greater risks of late events.
Two studies on acute ST-segment elevation myocardial
nfarction (STEMI) were presented at the ESC Hotlines.
he TRIANA (Tratamiento del Infarto Agudo de Miocar-
io en Ancianos [primary angioplasty vs. fibrinolysis in the
ery elderly]) trial was expected to randomly allocate 570
atients 75 years of age to primary angioplasty or throm-
olysis. The study had to be terminated prematurely with
nly 266 patients enrolled and did not meet the end point of
howing significant reduction of the combined end point of
eath, reinfarction, and disabling stroke with primary PCI
odds ratio [OR]: 1.46, 95% CI: 0.81 to 2.61, p  0.21 in
avor of primary PCI). Still, all components of the primary
nd point as well as major bleeding were lower in the
rimary PCI group, for example, a 3.0% incidence of
isabling stroke after thrombolysis versus 0.8% after PCI.
The NORDISTEMI (Norwegian Study on District
reatment of ST-Elevation Myocardial Infarction) trial
andomized patients with acute (6 h) STEMI admitted to
istrict general hospitals in an area of central-eastern Nor-
ay, remote from primary angioplasty centers (41). Conse-
uently, tenecteplase was administered to all patients, with
ne-half (n  132) treated conservatively in the center of
nitial admission and the remaining 134 immediately trans-
orted for an average of 158 km to the nearest angioplasty
enter. The primary end point of death, reinfarction, recur-
ent ischemia, and stroke at 12 months was not met (20.9%
s. 27.3%, p  0.18), but the secondary end point of death,
einfarction, and stroke was in favor of an immediate
ransfer.
rrhythmias and Pacing
significant number of studies focused on the mechanisms
f arrhythmogenesis. Jadidi et al. (42) used left atrial
igh-density mapping during sinus rhythm, coronary sinus
acing, and AF and found evidence of rhythm-dependent
unctional fractionation, which possibly reflects critical sites
or AF maintenance. Sossalla et al. (43) for the first time
howed that AF leads to electrical remodeling of sodium
urrents (INa), whereas INa inhibition by ranolazine proved
ntiarrhythmic.
In genetics, Benito et al. (44) established that in Brugada
yndrome, the presence of a mutation leading to a truncated
rotein is associated with a more than 3-fold increase in the
isk of sudden cardiac death or ventricular fibrillation in
rugada SCN5A mutation carriers, highlighting the need
or and efficacy of genetic testing in risk stratification.
Focusing on new diagnostic techniques and therapies of
rrhythmias, a number of studies reported novel findings.
he diagnostic value and cost effectiveness of implantable
oop recorders (ILRs) for syncope evaluation were indicated
n a study by Bajpai et al. (45), which recommends the
arly use of these devices in the assessment of patients
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yncopal symptoms.
In the REVISE (Reveal in the Investigation of Syncope
nd Epilepsy) study, Petkar et al. (46) used ILRs and
emonstrated that a high incidence of asystole in patients
isdiagnosed with epilepsy was present. An ECG-
ymptom correlation by ILR was shown in 59% of patients,
nd specifically demonstrated asystole in 26% of patients.
Remote monitoring of ICD patients is a new and
volving technique that offers a number of benefits in more
ersonalized health care for patients with devices. De Ruvo
t al. (47) found that patients with ST-segment elevation
ombined with an ICD (CRT-D) not remotely controlled
using a home monitoring system) had a 78% higher risk of
elayed detection of clinical adverse events within the first 6
onths from implantation, despite a follow-up program of
uarterly in-office visits. Varma et al. (48) reported on the
RUST (Lumos-T Safely Reduces Routine Office Device
ollow-Up) study, involving 1,312 patients implanted with
CDs with remote monitoring technology who were ran-
omly allocated 2:1 to remote monitoring or conventional
ffice visits. The results showed that event notification with
utomatic daily surveillance occurs infrequently, without
verburdening clinical resources, and provides rapid detec-
ion and notification of implant events.
The relatively innovative technique of remote magnetic
avigation for AF ablation was addressed in a number of
tudies. Chen et al. (49) evaluated 98 patients, (42% with
ersistent/permanent AF) who underwent radiofrequency
blation using a remote magnetic navigation system. Com-
lete pulmonary vein isolation was achieved in 96% of
atients, without major complications. At 12 2 months of
ollow-up, 73% of patients were free of AF. The second
tudy (50) concluded that AF ablation with remote mag-
etic navigation had similar procedure times but signifi-
antly decreased fluoroscopy times as compared with con-
entional ablation.
In another study, by Sommer et al. (51), it was deter-
ined that AF ablation in patients with HF significantly
mproved LV function (LVEF increased from 23% to 53%).
The results of various registries and clinical trials were
lso announced. Among the registries, the FINGER Bru-
ada registry stood out, presented by Probst et al. (52), in
hich 1,029 consecutive patients (745 males [72%]) were
ollowed up for 37 28 months. At initial enrollment, 64%
f the subjects were asymptomatic. During follow-up, it was
oted that the cardiac event rate per year was 7.7% for
atients with a history of aborted sudden death, 1.9% for
atients with syncope, and only 0.5% for asymptomatic
atients. It was also observed that the inducibility of
entricular tachyarrhythmias and a family history of sudden
eath were not predictive of cardiac events
Moss et al. (53), in the MADIT-CRT (Multicenter
utomatic Defibrillator Implantation Trial With Cardiac
esynchronization Therapy) examined whether CRT-D in
inimally symptomatic cardiac patients with ischemic heart iisease (NYHA functional class I or II) or nonischemic
eart disease (NYHA functional class II), QRS 130 ms,
nd LVEF 30% would reduce the combined end point of
ll-cause mortality or HF, when compared with ICD-only
herapy. With CRT-D, 34% reduction in death or HF was
bserved, with 41% reduction in HF events and improve-
ent in LVEF. Moreover, significant reverse LV remodel-
ng was observed on echocardiography.
Two substudies of the European cohort of the RE-
ERSE (Resynchronization Reverses Remodeling in Sys-
olic Left Ventricular Dysfunction) trial with a follow-up of
4 months were also important. Linde et al. (54) showed
hat CRT for mild HF improved clinical outcome, ventric-
lar structure and function, and modified disease progres-
ion with a more pronounced effect in NYHA functional
lass II patients. Gold et al. (55) showed that QRS duration
t baseline was a strong predictor of reverse LV remodeling.
Adequate selection of patients who may benefit most
rom CRT remains an intriguing topic. To further charac-
erize the patients who benefit, a substudy from the PROS-
ECT (Predictors of Response to CRT) trial, presented by
an Bommel et al. (56), compared patients with substantial
V reverse remodeling after 6 months of CRT with patients
ho did not show LV remodeling. Patients with extensive
emodeling after CRT were more often female, had non-
schemic HF, longer QRS duration, no history of ventric-
lar tachycardia, and extensive LV dyssynchrony on echo-
ardiography.
The RELY (Randomized Evaluation of Long-Term
nticoagulant Therapy) trial presented by Connolly et al.
57) compared dabigatran, a thrombin inhibitor, with war-
arin. In that trial, 18,113 patients with AF at risk for stroke
ere randomly assigned to blinded fixed doses of dabigatran
10 mg or 150 mg twice daily versus unblinded adjusted
arfarin. Median follow-up was 2.0 years, and the primary
utcome was stroke or systemic embolism. Rates of the
rimary outcome were 1.69% per year on warfarin versus
.53% per year on dabigatran 110 mg (RR: 0.91, 95% CI:
.74 to 1.11, p  0.001) and 1.11% per year on dabigatran
50 mg (RR: 0.66, 95% CI: 0.53 to 0.82, p  0.001).
ortality rates were 4.13% per year on warfarin versus
.74% per year on dabigatran 110 mg (p  0.13) and 3.64%
er year on dabigatran 150 mg (p  0.05). The study
oncluded that a dose of 150 mg of dabigatran twice daily
ignificantly reduced stoke compared with warfarin and had
similar risk of major bleeding. Dabigatran 110 mg twice
aily had a stroke rate similar to that of warfarin, with
ignificantly reduced major bleeding. Dabigatran had no
ajor toxicity, but did increase dyspepsia and gastrointesti-
al bleeding.
Finally, the new guidelines on the diagnosis and therapy
f syncope (58) emphasized that a new diagnostic approach
s necessary, focusing on risk stratification for SCD, for the
atient with an uncertain diagnosis on initial evaluation of a
yncopal episode. Furthermore, the guidelines stressed the
mportance of a diagnostic strategy based on prolonged
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2009 Scientific Sessions of the ESC December 15/22, 2009:2447–58CG monitoring (i.e., wearable/ILRs) in contrast to the
onventional strategy based on laboratory testing (i.e., tilt
esting and electrophysiological studies).
maging
clear shift to applications of imaging techniques to
ddress clinical dilemmas was noted. In the field of car-
iovascular magnetic resonance (CMR), data from the
uroCMR (European Cardiovascular Magnetic Reso-
ance) registry (59) were presented on 11,040 patients. The
esults demonstrated that patient management was altered
n 62% of cases based on CMR data, with a change of final
iagnosis in 16% of patients. In 82% of the examinations,
MR was able to satisfy all imaging needs. Similar data are
eeded from other modalities to get a better understanding
f imaging utilization and to base prospective randomized
rials on this experience.
Yilmaz et al. (60) used CMR to look into a group of false
ositive results of perfusion imaging (22 of 42 patients
ested in this selected population) and compared results with
nvasive coronary angiography. The authors concluded that
he majority of these patients either showed microvascular
ysfunction (13 patients) or epicardial coronary spasm (7
atients) during intracoronary acetylcholine. A significant
orrelation was found between a perfusion defect and
ypertension (r  0.61, p  0.01) and symptoms on
xertion (r  0.68, p  0.01). Although these patients
equire a treatment other than revascularization, they do
ave abnormalities and may thus not be considered real false
ositives.
Two studies looked into the use of myocardial salvage, in
ther words, the difference between the ultimate infarct size
assessed by contrast-enhanced CMR) and the area at risk
edema imaging) in the setting of ACS. One study (61)
nvolving 230 consecutive STEMI patients with early PCI
12 h) showed that the percent myocardium that can be
alvaged decreased in time after the onset of ischemia, but
ore slowly than was expected (73% within 2 h, 53% after
to 4 h, 38% after 6 to 8 h, 26% after 10 to 12 h), leaving
longer timeframe for opening the culprit vessel. The
alvage index was also a strong predictor of mortality (10%
bove median vs. 1% below median, p  0.003) and
emodeling (B coefficient 0.61, p  0.0001) (62); finally,
his salvage concept can be used as an outcome parameter in
arly intervention studies, aiming at myocardial protection.
In the field of positron emission tomography (PET), a
arge prognostic study on the use of flow reserve in addition
o perfusion was presented. Herzog et al. (63) applied
13-ammonia PET to evaluate perfusion and coronary flow
eserve in 256 patients. During a follow-up of 5.4 years, the
uthors demonstrated that flow reserve provided incremen-
al prognostic information over the perfusion data. Partic-
larly, patients who had normal perfusion but abnormal
oronary flow reserve had higher major CV event rate
4.9%) as compared with patients who had normal perfusion fnd normal flow reserve (1.3%, p  0.05); cardiac death
ates were 2.9% and 0.3% (p  0.05), respectively.
Mazurek et al. (64) investigated the potential role of
nflammation in the pericardial adipose tissue on progres-
ion and stability of coronary plaques. Standardized uptake
alue (as a measure of macrophage activity) on integrated
ET-computed tomography (CT) imaging was assessed in
he fat surrounding the coronary arteries and compared with
hat in the heart and other regions in 12 patients with
oronary artery disease and controls; standardized uptake
alue was significantly higher in the coronary fat of coronary
rtery disease patients (right coronary artery 0.86, left
ircumflex artery 1.34, left anterior descending artery 1.23)
ersus controls (right coronary artery 0.50, left circumflex
rtery 0.58, left anterior descending artery 0.59) or any other
at location (subcutaneous 0.21, visceral 0.40, right ventric-
lar epicardial 0.39). This finding could provide some
athophysiologic insight in this difficult area, but could also
urn out to be a good proxy to study interventions on plaque
nflammation.
Recurrence of AF after cardioversion remains a common
linical problem. De Vos et al. (65) evaluated the mechan-
cal properties of the atrial wall during AF using echocar-
iography with tissue Doppler imaging in 104 patients
eferred for electrical cardioversion; the derived AF-velocity
core was a strong predictor of AF recurrence (AF recur-
ence 78% in patients with AF-velocity score 2, as compared
ith AF recurrence 6% in patients with velocity score 0,
 0.01).
Various echocardiographic studies addressed long-term
utcome in patients with known or suspected coronary
rtery disease. In a large study involving 10,054 subjects
66), stress echocardiography provided useful prognostic
nformation (ischemia HR: 2.67, p  0.0001; resting wall
otion abnormalities HR: 1.41, p  0.0001), but an
schemic test on top of existing resting wall motion abnor-
alities or not had very different implications in normal
ubjects versus hypertensive subjects (hypertensive event
ates 42% and 40%, respectively, p  0.67; normotensive
vent rates 32% and 18%, respectively, p  0.02), illustrat-
ng that interpretation of test results needs to take into
ccount the clinical background of the patient.
In 2 studies from Australia, patient outcome in terms of
urvival after 5 years was evaluated on the basis of clinical
ndicators (535 and 546 patients); when LVEF or LV
nd-systolic volume was added to the model, derivation
rom 3-dimensional data (chi-square  7.5, p  0.006)
ather than 2-dimensional (chi-square  5.9, p  0.015)
roved to be superior (67). Similarly, the use of global
ongitudinal strain obtained with speckle tracking (HR: 1.5,
 0.001) was superior to LVEF (HR: 1.2, p  0.05) or
all motion scoring (HR: 1.3, p  0.01) (68). These results
ndicate that the mode of derivation and the method, in
ddition to the choice of physiologic parameter, are relevant
or the prognostic strength.
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nderstanding the pathophysiological mechanisms of val-
ular heart disease is important for potential therapeutic
pproaches. Lommi et al. (69) found that high-density
ipoprotein was decreased in aortic stenosis and that it
nduced osteoprotegerin secretion and decreased tumor
ecrosis factor- expression in cultured valvular cells. Thus,
igh-density lipoprotein may have a protective role inhib-
ting valve calcification. Rajamannan et al. (70) demon-
trated in a rabbit model that a hypercholesterolemic diet
ould lead to mitral valve thickening and induction of mitral
egurgitation. This effect was mediated through an Lrp5-
nduced cartilage phenotype that could be attenuated by
torvastatin. Herrmann et al. (71) showed that in severe
ortic stenosis, a low mean gradient was associated with a
ower longitudinal myocardial function assessed by strain
ate, a higher degree of fibrosis assessed by biopsy during
alve replacement, and worse long-term outcome.
Aortic stenosis quantification can be challenging when
entricular function is impaired. Cueff et al. (72) showed
hat aortic valve calcification score assessed by CT correlates
ith aortic valve area (r 0.66, p 0.0001). In a testing set
f 31 patients with reduced LVEF, it was confirmed that a
hreshold of 1651 Agatston Units confers a high sensitivity
92%) and specificity (86%), with a positive predictive value
f 96% for identification of severe aortic stenosis.
With regard to risk stratification, a score integrating
nformation of aortic jet velocity, brain natriuretic peptide
BNP), and sex was developed by Monin et al. (73) (score
AV Vel 2] [nat Log BNP 1.5] 1.5 [if female])
nd shown to predict event-free survival among patients
ith moderate and severe aortic stenosis. Rosenhek et al.
74) observed a high event rate (indication for aortic valve
eplacement in 90 patients; 6 cardiac deaths in previously
symptomatic patients) among 116 asymptomatic patients
ith very severe aortic stenosis defined by a peak aortic
et-velocity 5.0 m/s. Event-free survival was 36% and 12%
t 2 and 4 years, respectively, raising the question of
erforming early elective surgery in these patients.
Aortic valve disease is frequently associated with a dilated
scending aorta. Llibre Palares et al. (75) found a good
orrelation between transthoracic echocardiography and CT
or measurement of aortic diameters. Echocardiography
ppeared very accurate for the diagnosis of significant aortic
nlargement (50 mm) and may help to reduce radiation
xposure for such patients.
A systematic management strategy for the use of trans-
utaneous aortic valve implantation was proposed by Him-
ert et al. (76). Among 230 high-risk patients, the first step
as to rule out general contraindications to a transcutaneous
rocedure. In 83 patients, a transfemoral approach was
easible, whereas 37 patients were candidates for only a
ransapical approach. A total of 41 patients had specific
ontraindications to both methods—of whom 31 were then
cheduled for surgery. The strategy resulted in good out- eome, and a learning curve was observed. It has to be
ecognized that some patients cannot be treated by a
ranscutaneous approach. Contraindications to conventional
urgery are mostly related to comorbidity but can be due to
pecific technical/anatomical reasons; Taramasso et al. (77)
eported an excellent outcome for transcutaneous aortic
alve implantation in 31 such patients (15 with porcelain
orta, 4 with previous thoracotomy and open grafts).
Importantly, the new guidelines on the prevention, diag-
osis, and treatment of infective endocarditis were pre-
ented by the task force led by Habib (78). While the
rinciple of antibiotic prophylaxis in patients with predis-
osing cardiac conditions is maintained, it is now limited to
atients with the highest risk of endocarditis undergoing
igh-risk dental procedures. Particularly novel are the rec-
mmendations for the timing of surgery based on 3 main
ndication categories: HF, uncontrolled infection, and pre-
ention of embolism.
asic Science
he last few years have witnessed a great deal of progress in
dentifying genetic variants associated with common CVDs
ut have also highlighted the complexity and problems that
re associated with the interpretation of such a plethora of
ew and often unexpected findings. There are many genetic
ariants associated with coronary artery disease or MI; most
f them are common, and all of them appear to have a
elatively small effect on the risk of CVD. To date, it seems
nlikely that this newly acquired knowledge will add signif-
cantly to the predictive value of known risk factors of
oronary artery disease in individual patients; nevertheless,
hese findings have great potential for informing us of new
echanisms that underlie coronary artery disease and, by
oing so, for uncovering new therapeutic targets.
It should be noted that, when taken together, these
ariants still explain only a fraction of the genetic contribu-
ion to coronary artery disease, suggesting that epidemiology
ight have overestimated heritability, that the effect size of
ome variants might be underestimated by imperfect DNA
agging, or that epigenetic/environmental factors may inter-
ere with the penetrance of the associated disease in the
opulation.
The increased incidence of birth defects among obese
others may be explained by epigenetics, but how can we
emonstrate that this association is causal? This is a case
hen murine models can be very useful. For example,
ITED2 gene deletion is known to be associated with a
ariety of congenital malformations of the central nervous
nd CV system in a proportion of mice. To understand
hether the incomplete penetrance of CITED2 gene dele-
ion were susceptible to epigenetics, pregnant mice were fed
ith a high-fat diet inducing moderate obesity, and it was
ound that this intervention was sufficient to increase the
enetrance of cardiopulmonary laterality defects in the
mbryos of CITED2 deficient mothers. By analyzing the
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rofound impact on the molecular phenotype; in particular,
mong 40 transcripts affected by diet, they showed a
rofound reduction in Pitx2—a transcription factor that
nvolved determination of left-right asymmetry during de-
elopment. An interesting property of Pitx2 is to influence
he formation of the pulmonary myocardium, a structure
hat is known to have a crucial role in the pathogenesis of
F. Holm et al. (79) reported an association between AF
nd a variant in the ZFHX3 gene (encoding for a putative
egulator of Pitx2 expression) on chromosome 16q22 (OR:
.21, p  1.4  1010). This variant was also associated
ith ischemic stroke (OR: 1.11, p  0.00054) and cardio-
mbolic stroke (OR: 1.22, p  0.00021). These intriguing
ndings suggest that AF might account for a greater
ercentage of strokes than it had previously been envisaged,
r that genetic variations in the ZFHX3 gene may contrib-
te a common pathway to the pathogenesis of both cere-
rovascular disease and AF.
The proinflammatory and adverse paracrine actions of
erivascular adipose tissue have been highlighted by a
umber of investigators (80 – 82), providing yet another
echanism by which increased oxidative stress can lead
o the progression of atherosclerotic and CVD (83– 86).
n particular, the expression and activity of the small G
rotein, Rac1, was found to be increased in the atrial
yocardium of patients with AF (87) in association with
n increase in nicotinamide adenine dinucleotide phos-
ate (NADPH) oxidase-derived superoxide production.
reatment with rosuvastatin prevented AF in mice with
yocardial overexpression of Rac1, suggesting that pu-
ative antioxidant effects of statins may contribute a much
eeded “upstream” tool in the prevention of this common
rrhythmia. All the same, it seems unlikely that this
pproach would benefit all patients at risk of AF devel-
pment, as indicated by a meta-analysis of 15 trials on
tatins versus placebo that collected data on AF (68,504
andomized patients and 1,514 events) (88); in this large
ohort of patients, statin therapy did not reduce the risk
f AF (RR: 0.96, 95% CI: 0.87 to 1.07, p  0.49),
uggesting that previously reported benefits of statin
herapy on AF may be limited to specific groups of
atients (e.g., patients undergoing cardiac surgery, in
hich inflammation and atrial NADPH oxidase activity
ave been implicated in the new onset of AF in the
ost-operative period).
But are reactive oxygen species always “bad?” Maybe
ot, as suggested by direct activation of protein kinase G
the downstream effector of nitric oxide) by hydrogen
eroxide, leading to vasodilation. Similarly, protein ki-
ase A can be directly activated by reactive oxygen
pecies, causing positive inotropy in the myocardium.
hese findings indicate that signaling that has been
anonically associated with endothelial shear stress or
eta-adrenergic receptor stimulation can be activated
ndependently by the redox state of the cell.cknowledgments
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